Factor P Antibody (Monoclonal - #2)

A murine monoclonal antibody to an epitope on Factor P.


Product Specifications

Citations8
Clonality

Monoclonal

Immnogen

Purified human protein.

Applications

See citations and technical data sheet for application info.

Concentration1.0-1.2 mg/mL
ConjugateUnconjugated
Cross Reactivity

Human

Ordering Information

For Research Use Only in the United States. Not for use in diagnostic procedures.
Catalog NumberA235
Catalog Number (CE)N/A
Size100 µl
Price (USD)$365.00
Price (EURO)330,00 €

Contact us

US Phone+1 (858) 552 1100
EU Phone+353 (91) 412 474
US Emailcontact-us@quidelortho.com
EU Emailcontact-emea@quidelortho.com

Specifications

Description

A murine monoclonal antibody to an epitope on Factor P.

Size

100 µl

Concentration1.0-1.2 mg/mL
ApplicationsSee citations and technical data sheet for application info.
FormLiquid. Borate Buffered Saline (pH 8.4 ± 0.2), with ≤ 0.1% Sodium Azide.
ClonalityMonoclonal
Immunogen

Purified human protein.

ConjugateUnconjugated
Cross ReactivityHuman
Isotype

IgG1k

Purity

≥ 95% by SDS PAGE

SourceMouse
Specificity

This monoclonal antibody was raised against purified human Factor P. It does not inhibit function of Factor P.

Storage

Short term (30 days) 4˚C. Long term at or below –20˚C.

Background

The function of Properdin (Factor P) is to stabilize the alternative pathway convertase. Its binding to C3bBb extends the half-life of the complex. The concentration in plasma is approximately 20 μg/mL. Factor P has a molecular weight of 224 kDa, consisting of four identical chains of approximately 53 kDa molecular weight. The alternative complement pathway provides innate protection against microbial agents in the absence of specific antibody. The activation of this complement pathway can be triggered by a variety of substances, including microbial polysaccharides or lipids, gram-negative bacterial lipopolysaccharides, and surface determinants present on some viruses, parasites, virally infected mammalian cells and cancer cells. In autoimmune diseases, the alternative complement pathway may contribute directly to tissue damage.